Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply

JAMA Oncol. 2024 Apr 1;10(4):537-538. doi: 10.1001/jamaoncol.2023.6960.

Authors

Jens Huober¹, Beat Thürlimann², Daniel Dietrich³

Affiliations

¹ Breast Center St Gallen, Cantonal Hospital, St Gallen, Switzerland.
² Swiss Breast Care, Klinik Bethanien, Zürich, Switzerland.
³ Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.

PMID: 38329767
DOI: 10.1001/jamaoncol.2023.6960

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / pathology
Female
Humans
Receptor, ErbB-2
Trastuzumab

Substances

Trastuzumab
pertuzumab
Antibodies, Monoclonal, Humanized
Receptor, ErbB-2
ERBB2 protein, human